Pfizer to Buy Arena at 100% Premium in $6.7 Billion Deal

Pfizer just happened to buy company (with our tax dollars from vaccines) that treats immuno-inflammatory diseases (the covid vax causes long term).

Pfizer Inc. agreed to buy Arena Pharmaceuticals Inc. in a deal valued at about $6.7 billion that brings potential therapies targeting immuno-inflammatory diseases.

The drug giant will pay $100 a share in an all-cash transaction for San Diego-based Arena and its assets in gastroenterology, dermatology and cardiology, according to a statement Monday. That’s about double Arena’s Friday closing price. 

Leave a Reply

Your email address will not be published. Required fields are marked *